Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

1.6K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.6K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

204
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
204
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

331
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
331
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

383
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
383
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.0K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.0K
Drug Therapy01:28

Drug Therapy

40
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
40

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Tribute to Prof. Jules Angst highlighting his Contributions to Clozapine.

Pharmacopsychiatry·2026
Same author

Ketamine-assisted psychotherapy for posttraumatic stress disorder: a systematic review and individual participant data meta-analysis of predictors of treatment effects.

Psychotherapy and psychosomatics·2026
Same author

Forensic outcome in schizophrenia: It's the system, not the symptoms.

Comprehensive psychiatry·2026
Same author

Factors associated with the occurrence and persistence of subthreshold and full attention-deficit hyperactivity disorder in women: A population-based epidemiological study.

PloS one·2026
Same author

Attenuating trauma- and cocaine-related intrusions by blocking memory reconsolidation with minocycline: protocol for a transdiagnostic randomized controlled trial.

European journal of psychotraumatology·2026
Same author

Validation of smartphone-based heart rate variability measurement against ECG in patients with depression.

European archives of psychiatry and clinical neuroscience·2026
Same journal

The Clinical Threshold for Treatment in Psychiatry.

JAMA psychiatry·2026
Same journal

Semaglutide in Schizophrenia-A Top Clinical Trial.

JAMA psychiatry·2026
Same journal

Adolescent Peers' Diagnoses and Genetic Predispositions and Subsequent Risk of Mental Disorders.

JAMA psychiatry·2026
Same journal

Use and Misuse of GLP-1 Receptor Agonists Among People With Eating Disorders.

JAMA psychiatry·2026
Same journal

Connectivity- vs Scalp-Based Targeting of Accelerated Transcranial Magnetic Stimulation for Depression: A Randomized Clinical Trial.

JAMA psychiatry·2026
Same journal

Neurometabolites and Antipsychotic Response in Psychosis: A Mega-Analysis.

JAMA psychiatry·2026
See all related articles

Related Experiment Video

Updated: Jun 13, 2025

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

22.8K

Amygdala Reactivity, Antidepressant Discontinuation, and Relapse.

Tore Erdmann1, Isabel M Berwian2,3, Klaas Enno Stephan3,4

  • 1Applied Computational Psychiatry Lab, Mental Health Neuroscience Department, Division of Psychiatry and Max Planck Centre for Computational Psychiatry and Ageing Research, Queen Square Institute of Neurology, University College London, London, United Kingdom.

JAMA Psychiatry
|September 11, 2024
PubMed
Summary
This summary is machine-generated.

Antidepressant discontinuation increases relapse risk. Increased amygdala reactivity after stopping medication is linked to depression relapse, serving as a potential marker for clinical decisions.

More Related Videos

A Prediction Error-driven Retrieval Procedure for Destabilizing and Rewriting Maladaptive Reward Memories in Hazardous Drinkers
08:05

A Prediction Error-driven Retrieval Procedure for Destabilizing and Rewriting Maladaptive Reward Memories in Hazardous Drinkers

Published on: January 5, 2018

9.7K
The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice
07:13

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice

Published on: October 24, 2018

17.4K

Related Experiment Videos

Last Updated: Jun 13, 2025

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

22.8K
A Prediction Error-driven Retrieval Procedure for Destabilizing and Rewriting Maladaptive Reward Memories in Hazardous Drinkers
08:05

A Prediction Error-driven Retrieval Procedure for Destabilizing and Rewriting Maladaptive Reward Memories in Hazardous Drinkers

Published on: January 5, 2018

9.7K
The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice
07:13

The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice

Published on: October 24, 2018

17.4K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Neuroimaging

Background:

  • Antidepressant discontinuation significantly elevates the risk of depression relapse.
  • The neurobiological underpinnings of this relapse risk remain largely unknown.
  • Amygdala reactivity to negative stimuli is a key indicator of affective processing in depression, modulated by antidepressant treatment.

Purpose of the Study:

  • To determine if amygdala reactivity to negative facial emotions changes following antidepressant discontinuation.
  • To investigate the association between altered amygdala reactivity and the risk of subsequent depression relapse.

Main Methods:

  • Longitudinal observational study (Antidepressiva Absetzstudie [AIDA]) involving patients with remitted major depressive disorder (MDD).
  • Two task-based functional magnetic resonance imaging (fMRI) scans measuring amygdala reactivity.
  • Randomized discontinuation of antidepressants before or after the second fMRI scan, with 6-month relapse monitoring.

Main Results:

  • Initial amygdala reactivity did not differ between patients with remitted MDD and healthy controls.
  • An increase in amygdala reactivity post-discontinuation was significantly associated with depression relapse (P=.04).
  • Changes in amygdala reactivity predicted shorter time to relapse and were predictive of relapse (balanced accuracy, 67%).

Conclusions:

  • Increased amygdala reactivity following antidepressant discontinuation is linked to a higher risk of depression relapse.
  • This change in amygdala reactivity may serve as a functional neuroimaging marker.
  • Findings could inform clinical strategies for managing antidepressant discontinuation.